Maxime Parent-Michaud1, Philippe J Dufresne2, Eric Fournier2, Benjamin Folch3, Christine Martineau2, Sandrine Moreira2, Nicolas Doucet3, Louis De Repentigny1, Simon F Dufresne1,4. 1. Department of Microbiology, Infectious Diseases and Immunology, University of Montreal, Montreal, Quebec, Canada. 2. Laboratoire de santé publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, Quebec, Canada. 3. INRS-Institut Armand Frappier, University of Quebec, Laval, Quebec, Canada. 4. Division of Infectious Diseases and Clinical Microbiology, Department of Medicine, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
Abstract
OBJECTIVES: Azole resistance among Aspergillus fumigatus isolates is a growing concern worldwide. Induction of mutations during azole therapy, environment-acquired mutations caused by azole fungicides and intrinsic resistance of cryptic Fumigati species all contribute to the burden of resistance. However, there is a lack of data in Canada on this emerging threat. METHODS: To gain insights into the magnitude and mechanisms of resistance, a 14 year collection of Aspergillus section Fumigati comprising 999 isolates from 807 patients at a Montreal hospital was screened for azole resistance, and resistance mechanisms were investigated with the combined use of genome sequencing, 3D modelling and phenotypic efflux pump assays. RESULTS: Overall azole resistance was low (4/807 patients; 0.5%). A single azole-resistant A. fumigatus sensu stricto strain, isolated from a patient with pulmonary aspergillosis, displayed efflux-pump-mediated resistance. Three patients were colonized or infected with azole-resistant cryptic Fumigati species (one Aspergillus thermomutatus, one Aspergillus lentulus and one Aspergillus turcosus). Evidence is presented that azole resistance is efflux-pump-mediated in the A. turcosus isolate, but not in the A. lentulus and A. thermomutatus isolates. CONCLUSIONS: Azole resistance is rare in our geographic area and currently driven by cryptic Fumigati species. Continued surveillance of emergence of resistance is warranted.
OBJECTIVES:Azole resistance among Aspergillus fumigatus isolates is a growing concern worldwide. Induction of mutations during azole therapy, environment-acquired mutations caused by azole fungicides and intrinsic resistance of cryptic Fumigati species all contribute to the burden of resistance. However, there is a lack of data in Canada on this emerging threat. METHODS: To gain insights into the magnitude and mechanisms of resistance, a 14 year collection of Aspergillus section Fumigati comprising 999 isolates from 807 patients at a Montreal hospital was screened for azole resistance, and resistance mechanisms were investigated with the combined use of genome sequencing, 3D modelling and phenotypic efflux pump assays. RESULTS: Overall azole resistance was low (4/807 patients; 0.5%). A single azole-resistant A. fumigatus sensu stricto strain, isolated from a patient with pulmonary aspergillosis, displayed efflux-pump-mediated resistance. Three patients were colonized or infected with azole-resistant cryptic Fumigati species (one Aspergillus thermomutatus, one Aspergillus lentulus and one Aspergillus turcosus). Evidence is presented that azole resistance is efflux-pump-mediated in the A. turcosus isolate, but not in the A. lentulus and A. thermomutatus isolates. CONCLUSIONS:Azole resistance is rare in our geographic area and currently driven by cryptic Fumigati species. Continued surveillance of emergence of resistance is warranted.
Authors: A Espinel-Ingroff; D J Diekema; A Fothergill; E Johnson; T Pelaez; M A Pfaller; M G Rinaldi; E Canton; J Turnidge Journal: J Clin Microbiol Date: 2010-06-30 Impact factor: 5.948
Authors: Barbora Kozlikova; Eva Sebestova; Vilem Sustr; Jan Brezovsky; Ondrej Strnad; Lukas Daniel; David Bednar; Antonin Pavelka; Martin Manak; Martin Bezdeka; Petr Benes; Matus Kotry; Artur Gora; Jiri Damborsky; Jiri Sochor Journal: Bioinformatics Date: 2014-05-29 Impact factor: 6.937
Authors: Eveline Snelders; Anna Karawajczyk; Gijs Schaftenaar; Paul E Verweij; Willem J G Melchers Journal: Antimicrob Agents Chemother Date: 2010-04-12 Impact factor: 5.191
Authors: A Alastruey-Izquierdo; E Mellado; T Peláez; J Pemán; S Zapico; M Alvarez; J L Rodríguez-Tudela; M Cuenca-Estrella Journal: Antimicrob Agents Chemother Date: 2013-05-13 Impact factor: 5.191
Authors: Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning Journal: Emerg Infect Dis Date: 2009-07 Impact factor: 6.883
Authors: S Imbert; A C Normand; S Cassaing; F Gabriel; L Kristensen; C Bonnal; L Lachaud; D Costa; J Guitard; L Hasseine; M Palous; M Piarroux; M Hendrickx; R Piarroux; A Fekkar Journal: Antimicrob Agents Chemother Date: 2020-11-17 Impact factor: 5.191